



New chiral thiols and C₂-symmetrical disulfides of *Cinchona* alkaloids: ligands for the asymmetric Henry reaction catalyzed by Cu^{II} complexes

Mariola Zielińska-Błajet, Jacek Skarżewski *

Department of Organic Chemistry, Faculty of Chemistry, Wrocław University of Technology, 50-370 Wrocław, Poland

ARTICLE INFO

Article history:

Received 26 June 2009

Accepted 2 July 2009

Available online 10 August 2009

ABSTRACT

Seven *Cinchona* alkaloids were reacted with thioacetic acid and Bu₃P/diethyl diazadicarboxylate in THF at 0–25 °C to give the corresponding thiolacetates with complete inversion of configuration at the substitution center. The thus obtained chiral thioesters were converted into thiols and these compounds were oxidized to the respective disulfides of C₂-symmetry. Both C-9 thioles and disulfides were tested as chiral ligands in the Cu-catalyzed asymmetric Henry reaction. When the thiol derivatives of an 8,9-*like* configuration were applied in the reaction of benzaldehyde and nitromethane, the obtained nitroaldol was of the same absolute configuration as the catalyst and the observed enantioselectivity was up to 83% ee. These ligands gave higher ees than the corresponding thioethers, disulfides, and thioles of 8,9-*unlike* configuration. The results obtained are in agreement with the proposed transition-state model involving nucleophilic attack of a deprotonated nitromethane directed preferably at one side of the O-complexed benzaldehyde.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

The most noteworthy achievements in asymmetric synthesis can be ascribed to the application of *privileged catalysts*, effective in numerous mechanistically different, enantioselective transformations.¹ Among these successful catalysts are derivatives of *Cinchona* alkaloids. In some cases, the C₂-symmetry of such chiral ligands plays an important role in their effectiveness, as is well documented for the Sharpless dihydroxylations, Michael additions, and other asymmetric processes.² Recently, we have synthesized a series of 9-phenylsulfenyl- and 9-phenylselenenyl-derivatives of *Cinchona* alkaloids and demonstrated their catalytic performance in the enantioselective Tsuji-Trost allylic alkylation.³ Both types of derivatives constitute chiral bifunctional chalcogen/nitrogen-donating ligands. The ligands of this sort have been successfully used in various transition-metal catalyzed stereoselective reactions.⁴ However, their chiral complexes with copper have hardly been tested⁵ and their use as S/N-donating ligands in the enantioselective copper-catalyzed nitroaldol (Henry) reaction have not yet been described. Moreover, only a few derivatives of *Cinchona* alkaloids have already been described as catalysts for the asymmetric Henry reaction.⁶

Herein we report the synthesis of unknown *Cinchona* alkaloid C-9 thiols, which were subsequently oxidized to the corresponding dimeric disulfides of C₂ symmetry. We examined both thiols and

disulfides as prospective chiral ligands in the Cu(II) catalyzed nitroaldol reaction.⁷

2. Results and discussion

2.1. Ligands synthesis

Commercially available *Cinchona* alkaloids, namely cinchonidine (CD), quinine (QN), and quinidine (QD), the respective dihydro derivatives (DHQN/DHQD), and their synthetic C-9-*epi*-configured analogues (*epi*-QN/*epi*-QD)⁹ were used as starting materials (Fig. 1). In order to transform these secondary alcohols into thiols we attempted the nucleophilic substitution of the corresponding mesylates with thiocyanate, thiourea, or thioacetate sodium salt. All these efforts failed and finally, the native and *epi*-alkaloids **1a–g** were directly converted into the corresponding thioesters **2a–g** using a Mitsunobu reaction.⁸ The mixtures of **1a–g** and thioacetic acid were treated with the preformed adduct of Ph₃P and DEAD in THF at 0 °C and then left at room temperature for 3–7 days. The resulting thioacetates **2a–g** were isolated by chromatography in 42–59% yield along with the recovered alkaloids (ca. 20–30%) and a small amount of unidentified compounds with the rearranged alkaloid skeleton. In all cases the thioesters were obtained as a single diastereomer and inversion of configuration at the stereogenic center C-9 of alkaloids was observed. The results are summarized in Scheme 1 and Table 1.

In the next step, we reduced the thioesters obtained with lithium aluminum hydride to obtain the required thiols **3a–g** in

* Corresponding author. Tel.: +48 71 320 2464; fax: +48 71 328 4064.
E-mail address: jacek.skarzewski@pwr.wroc.pl (J. Skarżewski).





Figure 1. The structure of Cinchona alkaloids.

excellent chemical yields (up to 93%). These products were easily oxidized by iodine in ethanol to give the corresponding disulfides of Cinchona alkaloids **4a–g** (80–99%) (Table 2). Compounds **4** are clearly C₂-symmetric, as shown by their NMR spectra, which resemble those of the corresponding thiols. Simultaneously, smaller values of the specific rotation were recorded for disulfides than for the parent thiols. As expected, the shelf-life of the thiols was rather limited. The more stable disulfides can be regarded as their 'protected derivatives', and could be regenerated to the appropriate pure thiols with LAH.



Scheme 1.

Table 1
Synthesis of thiolacetates **2**

Entry	Alkaloid 1	Config.	Thiolester 2	Yield (%)	$[\alpha]_D$ (CH ₂ Cl ₂)	Config.
1	CD 1a	(8S,9R)	9-CH ₃ COS- <i>epi</i> -CD 2a	59	-21.8	(8S,9S)
2	QN 1b	(8S,9R)	9-CH ₃ COS- <i>epi</i> -QN 2c	43	-11.0	(8S,9S)
3	DHQN 1c	(8S,9R)	9-CH ₃ COS- <i>epi</i> -DHQN 2c	53	-14.2	(8S,9S)
4	QD 1d	(8R,9S)	9-CH ₃ COS- <i>epi</i> -QD 2d	42	+87.0	(8R,9R)
5	DHQP 1e	(8R,9S)	9-CH ₃ COS- <i>epi</i> -DHQP 2e	44	+62.5	(8R,9R)
6	<i>epi</i> -QN 1f	(8S,9S)	9-CH ₃ COS-QN 2f	49	+38.1	(8S,9R)
7	<i>epi</i> -QD 1g	(8R,9R)	9-CH ₃ COS-QD 2g	44	+64.9	(8R,9S)

Table 2
Synthesis of thiols **3** and disulfides **4**

Entry	Thiol 3	Yield (%)	$[\alpha]_D$ (CH ₂ Cl ₂)	Disulfides 4	Yield (%)	$[\alpha]_D$ (CH ₂ Cl ₂)	Config.
1	3a	73	-58.1	9- <i>epi</i> -CD-S-) ₂ 4a	90	-35.0	(8S,9S)
2	3b	80	-72.8	9- <i>epi</i> -QN-S-) ₂ 4b	99	-25.8	(8S,9S)
3	3c	84	-46.0	9- <i>epi</i> -DHQN-S-) ₂ 4c	98	-9.1	(8S,9S)
4	3d	93	+148.9	9- <i>epi</i> -QD-S-) ₂ 4d	96	+94.1	(8R,9R)
5	3e	77	+141.4	9- <i>epi</i> -DHQP-S-) ₂ 4e	88	+46.8	(8R,9R)
6	3f	93	+23.7	9-QN-S-) ₂ 4f	98	+15.4	(8S,9R)
7	3g	65	+106.0	9-QD-S-) ₂ 4g	82	+73.0	(8R,9S)

2.2. Catalytic asymmetric Henry reaction

With the aforementioned set of chiral thiols and disulfides in hand, we examined their catalytic performance in the nitroaldol reaction. The model reaction between benzaldehyde and nitromethane was carried out in the presence of 12 mol% of chiral ligand and 10 mol% of hydrated copper acetate (Scheme 2). The screening experiments are summarized in Table 3. We tested a series of solvents (dichloromethane, acetonitrile, isopropanol, etc.) and *i*-PrOH was chosen as the most appropriate one. Moreover, we noted that in the absence of a ligand, the expected nitroaldol product did not form at all. Thus, all the ligands formed complexes that catalyzed the reaction giving nitroaldol in good yield. Generally, higher enantioselectivities were obtained for the thiols of 8,9-like configuration [e.g., (8S,9S)] **3a–d** (43–83% ee) in comparison to the respective disulfides **4a–d** (34–52% ee). However, the thiols of 8,9-unlike configuration, obtained from *epi*-quinine **3f** and *epi*-quinidine **3g** performed worse (14% and 17% ee, respectively). The best result was observed for **3b** (9-HS-*epi*-QN) in *i*-PrOH (70% yield and 83% ee), while for dichloromethane or acetonitrile, the yield and selectivity were significantly less (13–18%, 43–44% ee). Moreover, the addition of 5 mol% of Et₃N lowered the enantioselectivity from 83% to 28%. We tested the reaction of cyclohexanecarboxaldehyde with nitromethane which gave the corresponding Henry product in 64% yield and 75% ee. For comparison the thioether available from the earlier study (9-PhS-*epi*-QN)³ was also tested (Table 3, entry 13).

The encouraging results obtained for the addition of nitromethane prompted us to extend this reaction to other nitroalkanes. Thus the reaction of nitroethane with benzaldehyde as carried out before in the presence of **3b**/Cu(OAc)₂ at 0 °C mainly gave the *syn*-product in 76% ee. Lowering the temperature to -20 °C led to an improvement in both diastereo- and enantioselectivity (Table 4). Furthermore, the addition of bulkier 2-phenylnitroethane to benze-




Table 3
Nitroaldol reaction of benzaldehyde and nitromethane catalyzed by ligand/Cu(OAc)₂^a

Entry	Ligand	Yield (%)	ee ^b (%) abs. config. ^c
1	9-HS- <i>epi</i> -CD 3a	93	55 (S)
2	9-HS- <i>epi</i> -QN 3b	70	83 (S)
3	9-HS- <i>epi</i> -QN 3b ^f	64 ^f	75 (S) ^f
4	9-HS- <i>epi</i> -QN 3b ^d	13	43 (S)
5	9-HS- <i>epi</i> -QN 3b ^e	18	44 (S)
6	9-HS- <i>epi</i> -DHQN 3c	43	54 (S)
7	9-HS- <i>epi</i> -QD 3d	48	44 (R)
8	9-HS-QN 3f	63	14 (S)
9	9-HS-QD 3g	51	17 (R)
10	9- <i>epi</i> -CD- <i>S</i> - ₂ 4a	72	47 (S)
11	9- <i>epi</i> -QN- <i>S</i> - ₂ 4b	80	52 (S)
12	9- <i>epi</i> -QD- <i>S</i> - ₂ 4d	79	34 (R)
13	9-PhS- <i>epi</i> -QN	99	18 (R)

^a The reactions were carried out on a 0.5 mmol scale, 12 mol % of respective ligand, 10 mol % of Cu(OAc)₂·H₂O, 10 equiv of CH₃NO₂ in *i*-PrOH (2 mL) at 0 °C for 3 days.

^b Enantiomeric excess determined by HPLC analysis.

^c Determined by comparison of the specific rotation value and retention time (chiral HPLC) with literature values.

^d Reaction was performed in MeCN.

^e Reaction was performed in CH₂Cl₂.

^f The reaction of cyclohexanecarboxaldehyde with nitromethane.

Table 4
Henry reaction of benzaldehyde and nitroalkanes catalyzed by **3b**/Cu(OAc)₂^a

Entry	R	T (°C)	Yield ^b (%)	syn/anti ^c	ee [syn](%) ^{d,e}	ee [anti](%) ^{d,e}
1	Me	0	98	65:35	76 (1 <i>S</i> ,2 <i>S</i>)	37 (1 <i>S</i> ,2 <i>R</i>)
2	Me	-20	98	71:29	86 (1 <i>S</i> ,2 <i>S</i>)	50 (1 <i>S</i> ,2 <i>R</i>)
3	PhCH ₂	-20	71	43:57	74 (1 <i>S</i> ,2 <i>S</i>)	61 (1 <i>S</i> ,2 <i>R</i>)

^a The reactions were carried out on a 0.5 mmol scale, 12 mol % of respective ligand, 10 mol % of Cu(OAc)₂·H₂O, 10 equiv of CH₃NO₂ in *i*-PrOH (2 mL) for 3 days.

^b Combined yields of *syn* and *anti* isomers.

^c Determined by ¹H NMR spectroscopy of the crude product.

^d Determined by chiral HPLC.

^e The absolute configurations were established by comparison with literature data.

aldehyde afforded both *anti*- and *syn*-products in almost equal amounts, although with similar enantioselectivity.

In agreement with the previously reported transition-state models,^{7h,9a,b} we assume that in the Cu(II)-(8*S*,9*S*)-**3b** catalytic complex the carbonyl oxygen atom is coordinated at one of the equatorial positions. As a consequence, deprotonated nitromethane binds its oxygen atom to the metal center from the axial side. This positioning of the reactants seems to be the most favorable orientation when taking into account both steric repulsion and electronic activation. Moreover, it seems that the hydrogen bonds formed by the sulfhydryl group additionally stabilize such a molecular arrangement. This clearly leads to the favored *Re face* attack (Fig. 2), giving the observed (*S*)-product. The absence of a methoxy group in the ligand structure 9-HS-*epi*-CD, (8*S*,9*S*)-**3a** leads to the less-stabilized transition-state and 55% ee only (Table 3, entry 1).

This transition-state model is also in agreement with the observed reversal of the stereochemical outcome of the catalytic reaction for (8*R*,9*R*)-**3d**. For that complex, one may expect a nearly




Figure 2. Proposed geometry of the transition-state model for the Cu(II)-(8*S*,9*S*)-**3b** complex.

enantiomeric situation, hence the corresponding positioning of the reactants seems favorable for the nitronate ion approaching benzaldehyde from the *Si face* to give the (*R*)-product, in fact obtained as a main product in this case.

Interestingly, we observed also an opposite stereochemical outcome of the catalytic reaction when instead of 9-HS-*epi*-QN **3b**, the corresponding thioether 9-PhS-*epi*-QN was used (see Table 3, entry 13). In this case, a large phenyl moiety placed instead of the sulfhydryl hydrogen strongly hampers the previously favored orientation. Here, the stereochemical result seems to depend on which of the two free electron pairs of sulfur better coordinate the copper ion, thus stabilizing the respective catalytic complex. The same applies to the reaction catalyzed by C₂-symmetric disulfides. The lowest enantioselectivities observed for the ligands of 8,9-*unlike*-configuration **3f** and **3g** suggest that they form at least two complexes of similar energy, differing in their coordination modes. A similar outcome was previously observed for the Tsuji-Trost reaction catalyzed by the respective phenylsulfenyl *Cinchona* derivatives, namely for 9-PhS-*epi*-QD, 78% ee and for 9-PhS-QD, 12% ee.³

Interestingly, the experiments testing the scope of the catalytic Henry reaction (Scheme 3, Table 4) show that other nitronates add to benzaldehyde mainly from the *Re face*, in the fashion depicted in Figure 2, leading to (1*S*)-propanols as the major products. The process is kinetically controlled, so lowering temperature (to -20 °C) increased its selectivity. However, if the observed diastereoselectivity for nitroethane (42% de, *syn*) can be accounted for by the preferred configuration of the corresponding nitronate anion, a loss of diastereoselectivity in the reaction of 2-phenylnitroethane remains unclear.


3. Conclusion

In conclusion, we have presented a useful stereospecific synthesis of C-9 thiols and disulfides of *Cinchona* alkaloids. The thiols of 8,9-*like* configuration obtained from the native alkaloids were successful chiral ligands in the copper-catalyzed asymmetric nitroaldol reaction. The reaction of benzaldehyde with nitromethane in the presence of 12 mol % of ligand and 10 mol % of Cu(OAc)₂ in isopropanol gave the corresponding product in good yield and with up to 83% ee. The reaction stereochemical outcome is in agreement with the generally accepted transition-state model involving coordination of both reacting species to the central metal ion.

4. Experimental

4.1. General

Melting points were determined using a Boetius hot-stage apparatus and are uncorrected. IR spectra were recorded on a Perkin Elmer 1600 FTIR spectrophotometer. ¹H NMR and ¹³C NMR spectra were measured on a Bruker CPX (¹H, 300 MHz) spectrometer using TMS as an internal standard. Optical rotations at 578 nm



Scheme 3.

were measured using an Optical Activity Ltd. Model AA-5 automatic polarimeter. The enantiomeric composition of the nitroalcohols was determined by HPLC analysis using a chiral stationary phase (Chiracel OD-H or Daicel Chiralpak AD-H). The absolute configuration was assigned by comparison of the retention time and the sign of the specific rotation with the literature.

Separations of products by chromatography were performed on Silica Gel 60 (230–400 mesh) purchased from Merck. TLC was performed using Silica Gel 60 precoated plates (Merck). All solvents were purified and dried by standard methods. The starting Cinchona alkaloids were commercially available, *epi*-quinine and *epi*-quinidine were prepared according to a general procedure described in the literature.^{3a}

4.2. General procedure for the synthesis of thiolacetates of cinchona alkaloids 2

To a solution of triphenylphosphine (1.049 g, 4 mmol) in dry THF (10 mL) was added DEAD (0.697 g, 0.622 mL, 04 mmol). The mixture was stirred at 0 °C under an argon atmosphere for 30 min. A yellow precipitate resulted. Then solutions of appropriate alkaloids (2 mmol) in THF (10 mL) and thioacetic acid (0.304 g, 0.286 mL, 4 mmol) in THF (5 mL) were added for 10 min by a syringe and the mixture was stirred for additional 1 h at 0 °C. Next the mixture was allowed to warm to rt and it was further stirred for 3–7 days. Thereafter a yellow or brown solution was concentrated and then purified by column chromatography on silica gel (first CHCl₃/*t*-BuOMe, 1:1, next CHCl₃/MeOH, 40:3) gave the products as a yellow or brown oils.

4.2.1. (1S,3R,4S,8S,9S)-9-Acetylthiocinchonan (9-acetylthio-*epi*-cinchonidine, 9-CH₃COS-*epi*-CD) 2a

Yield 59%, yellow oil; $[\alpha]_D = -21.8$ (c 0.87, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.49–1.55 (m, 2H), 1.65–1.72 (m, 1H), 1.86–1.90 (m, 2H), 2.11 (s, 3H, SCOMe), 2.25–2.28 (m, 1H), 2.54–2.65 (m, 2H), 2.99–3.13 (m, 2H), 3.39 (q, *J* = 8.0 Hz, 1H), 4.98–5.04 (m, 2H, CH₂=), 5.78–5.89 (m, 1H, CH=), 6.53 (d, *J* = 7.3 Hz, 1H, C⁹H), 7.39 (d, *J* = 4.5 Hz, 1H, ArH), 7.59 (t, *J* = 8.2 Hz, 1H, ArH), 7.71 (t, *J* = 8.2 Hz, 1H, ArH), 8.13 (d, *J* = 8.5 Hz, 1H, ArH), 8.23 (d, *J* = 8.5 Hz, 1H, ArH), 8.89 (d, *J* = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.1, 24.5, 27.6, 27.8, 39.7, 42.4, 56.6, 59.6, 74.0, 114.5, 118.8, 123.4, 126.0, 126.9, 129.2, 130.5, 141.7, 145.3, 148.6, 150.0, 170.0; IR (film): 2943, 2866, 1747, 1637, 1509, 1453, 1372, 1232, 1024, 914, 758, 666 cm⁻¹. *R*_f = 0.52 (CHCl₃/MeOH, 40:3).

4.2.2. (1S,3R,4S,8S,9S)-6'-Methoxy-9-acetylthiocinchonan (9-acetylthio-*epi*-quinine, 9-CH₃COS-*epi*-QN) 2b

Yield 43%, yellow oil; $[\alpha]_D = -11.0$ (c 0.90, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.49–1.61 (m, 2H), 1.68–1.75 (m, 1H), 1.84–1.89 (m, 2H), 2.13 (s, 3H, SCOMe), 2.25–2.28 (m, 1H), 2.57–2.71 (m, 2H), 3.01–3.14 (m, 2H), 3.36 (q, *J* = 8.2 Hz, 1H), 3.96 (s, 3H, OMe), 4.98–5.05 (m, 2H, CH₂=), 5.78–5.90 (m, 1H, CH=), 6.49 (d, *J* = 7.3 Hz, 1H, C⁹H), 7.36 (d, *J* = 4.4 Hz, 1H, ArH), 7.38 (d, *J* = 2.7 Hz, 1H, ArH), 7.43 (d, *J* = 2.7 Hz, 1H, ArH), 8.01 (d, *J* = 9.2 Hz, 1H, ArH), 8.74 (d, *J* = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.2, 22.1,

23.9, 27.6, 39.5, 42.4, 55.8, 56.4, 58.9, 73.5, 101.4, 114.8, 118.7, 122.0, 126.9, 131.8, 141.4, 143.4, 144.7, 147.4, 158.0, 170.0; IR (film): 2942, 1746, 1622, 1509, 1474, 1371, 1231, 1030, 853, 755, 718, 665 cm⁻¹. *R*_f = 0.52 (CHCl₃/MeOH, 40:3).

4.2.3. (1S,3R,4S,8S,9S)-10,11-Dihydro-6'-methoxy-9-acetylthiocinchonan (9-acetylthio-*epi*-dihydroquinine, 9-CH₃COS-*epi*-DHQN) 2c

Yield 53%, brown oil; $[\alpha]_D = -14.2$ (c 0.20, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.86 (t, *J* = 7.3 Hz, 3H, Me), 1.27–1.35 (m, 2H), 1.51–1.66 (m, 3H), 1.73–1.87 (m, 3H), 2.16 (s, 3H, SCOMe), 2.36–2.41 (m, 1H), 2.70–2.79 (m, 1H), 3.08–3.22 (m, 2H), 3.36 (q, *J* = 7.9 Hz, 1H), 4.00 (s, 3H, OMe), 6.62 (d, *J* = 5.5 Hz, 1H, C⁹H), 7.33–7.41 (m, 2H, ArH), 7.46 (d, *J* = 2.5 Hz, 1H, ArH), 8.01 (d, *J* = 9.2 Hz, 1H, ArH), 8.74 (d, *J* = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 12.0, 21.1, 23.2, 25.2, 27.5, 27.9, 37.0, 42.5, 55.9, 57.9, 58.6, 73.2, 101.3, 118.4, 122.0, 126.8, 131.7, 143.2, 144.7, 147.3, 158.1, 169.7; IR (film): 2946, 1713, 1621, 1589, 1509, 1364, 1229, 1024, 855, 751, 718, 614 cm⁻¹. *R*_f = 0.56 (CHCl₃/MeOH, 40:4).

4.2.4. (1S,3R,4S,8R,9R)-6'-Methoxy-9-acetylthiocinchonan (9-acetylthio-*epi*-quinidine, 9-CH₃COS-*epi*-QD) 2d

Yield 42%, yellow oil; $[\alpha]_D = +87.0$ (c 0.50, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.44–1.58 (m, 3H), 1.82–1.91 (m, 2H), 2.15 (s, 3H, SCOMe), 2.23–2.32 (m, 1H), 2.68–2.86 (m, 2H), 2.93 (d, *J* = 8.9 Hz, 2H), 3.29 (q, *J* = 8.9 Hz, 1H), 3.96 (s, 3H, OMe), 5.07–5.14 (m, 2H, CH₂=), 5.98–6.09 (m, 1H, CH=), 6.54 (d, *J* = 6.8 Hz, 1H, C⁹H), 7.33–7.41 (m, 3H, ArH), 8.01 (d, *J* = 9.0 Hz, 1H, ArH), 8.73 (d, *J* = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.2, 23.3, 26.4, 27.9, 39.8, 49.2, 49.9, 55.6, 59.0, 73.6, 101.4, 114.9, 118.5, 121.9, 127.0, 131.8, 140.3, 143.8, 144.7, 147.4, 157.9, 170.0; IR (film): 2937, 2873, 1747, 1622, 1593, 1508, 1455, 1372, 1229, 1029, 847, 756, 717, 663 cm⁻¹. *R*_f = 0.46 (CHCl₃/MeOH, 40:3).

4.2.5. (1S,3R,4S,8R,9R)-10,11-Dihydro-6'-methoxy-9-acetylthiocinchonan (9-acetylthio-*epi*-dihydroquinidine, 9-CH₃COS-*epi*-DHQD) 2e

Yield 44%, brown oil; $[\alpha]_D = +62.5$ (c 0.26, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.95 (t, *J* = 7.2 Hz, 3H, Me), 1.23–1.35 (m, 2H), 1.53–1.67 (m, 5H), 1.83–1.89 (m, 1H), 2.21 (s, 3H, SCOMe), 2.94–3.35 (m, 5H), 4.04 (s, 3H, OMe), 6.96 (s, 1H, C⁹H), 7.27–7.29 (m, 1H, ArH), 7.38 (dd, *J* = 9.2, 2.3 Hz, 1H, ArH), 7.51 (d, *J* = 2.3 Hz, 1H, ArH), 8.01 (d, *J* = 9.2 Hz, 1H, ArH), 8.71 (d, *J* = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 11.6, 20.6, 21.1, 22.1, 25.0, 25.6, 35.9, 49.2, 49.8, 56.4, 58.0, 71.7, 100.9, 117.4, 122.8, 126.2, 131.4, 142.1, 144.4, 146.8, 158.7, 168.7; IR (film): 2946, 1755, 1621, 1509, 1368, 1229, 1027, 858, 753, 719, 663 cm⁻¹. *R*_f = 0.38 (CHCl₃/MeOH, 40:3).

4.2.6. (1S,3R,4S,8S,9R)-6'-Methoxy-9-acetylthiocinchonan (9-acetylthio-quinine, 9-CH₃COS-QN) 2f

Yield 49%, yellow oil; $[\alpha]_D = +38.1$ (c 0.42, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.83–0.90 (m, 1H), 1.35–1.41 (m, 1H), 1.65–1.73 (m, 3H), 2.09 (s, 3H, SCOMe), 2.36–2.41 (m, 1H), 2.83–2.94 (m, 2H), 3.26–3.40 (m, 2H), 3.61 (q, *J* = 7.4 Hz, 1H), 3.99 (s, 3H, OMe), 4.99–5.06 (m, 2H, CH₂=), 5.70–5.82 (m, 1H, CH=), 6.40 (d,

$J = 10.5$ Hz, 1H, C⁹H), 7.37–7.44 (m, 1H, ArH), 7.60 (d, $J = 2.7$ Hz, 1H, ArH), 8.04 (d, $J = 9.2$ Hz, 1H, ArH), 8.77 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 16.6, 20.4, 22.6, 23.4, 34.7, 36.5, 50.8, 50.9, 51.1, 54.2, 97.0, 109.9, 115.9, 117.2, 123.0, 127.1, 136.6, 137.1, 140.2, 142.8, 153.4, 165.8; IR (film): 2937, 2865, 1738, 1622, 1508, 1475, 1367, 1239, 1031, 854, 754, 716, 633 cm⁻¹. $R_f = 0.36$ (EtOAc/MeOH/Et₃N, 7:3:0.5).

4.2.7. (1S,3R,4S,8R,9S)-6'-Methoxy-9-acetylthiocinchonan (9-acetylthio-quinidine, 9-CH₃COS-QD) 2g

Yield 44%, yellow oil; $[\alpha]_D = +64.9$ (c 0.98, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.87–0.96 (m, 1H), 1.11–1.19 (m, 1H), 1.52–1.64 (m, 3H), 2.09 (s, 3H, SCOMe), 2.24–2.31 (m, 1H), 2.98–3.07 (m, 4H), 3.35 (q, $J = 9.5$ Hz, 1H), 3.99 (s, 3H, OMe), 5.05–5.14 (m, 2H, CH₂=), 5.82–5.93 (m, 1H, CH=), 6.44 (d, $J = 10.0$ Hz, 1H, C⁹H), 7.38–7.43 (m, 2H, ArH), 7.55 (d, $J = 2.7$ Hz, 1H, ArH), 8.02 (d, $J = 9.2$ Hz, 1H, ArH), 8.76 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.4, 24.2, 26.5, 27.4, 39.2, 47.7, 49.3, 55.6, 59.3, 70.5, 101.4, 114.7, 120.3, 122.2, 127.8, 131.8, 140.4, 142.4, 144.8, 147.5, 158.1, 170.6; IR (film): 2938, 2873, 1740, 1622, 1508, 1476, 1368, 1238, 1031, 851, 756, 716, 666 cm⁻¹. $R_f = 0.41$ (CHCl₃/MeOH, 40:3).

4.3. Representative procedure for the preparation of thiols of alkaloids 3

The appropriate thiolacetate of alkaloid (1.5 mmol) was dissolved in abs. Et₂O or THF (10 mL) and was added to a well-stirred suspension of LiAlH₄ (0.228 g, 6 mmol) in Et₂O or THF (10 mL) under an argon atmosphere. The reaction mixture was stirred at rt for 1–3 days and then quenched by the careful addition of ether saturated with water (5 mL) and aqueous solution of 20% NaOH (ca. 10 mL). The aqueous layer was extracted with Et₂O (3 × 15 mL) and the combined organic phase was washed with H₂O, brine, dried (Na₂SO₄) and the solvent was evaporated to afford a yellow solid or brown oil.

4.3.1. (1S,3R,4S,8S,9S)-9-Mercaptocinchonan (9-mercapto-epi-cinchonidine, 9-HS-epi-CD) 3a

Yield 73%, light yellow solid, mp 188–193 °C; $[\alpha]_D = -58.1$ (c 0.74, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.34–1.41 (m, 2H), 1.65–1.70 (m, 3H), 2.13–2.16 (m, 1H), 2.48–2.57 (m, 2H), 2.90–2.98 (m, 2H), 3.37–3.42 (m, 1H), 4.78–4.89 (m, 3H, CH₂=, SH), 5.54–5.66 (m, 2H, CH=, C⁹H), 7.24 (t, $J = 7.2$ Hz, 1H, ArH), 7.48 (d, $J = 4.5$ Hz, 1H, ArH), 7.53 (t, $J = 7.2$ Hz, 1H, ArH), 7.86 (d, $J = 8.2$ Hz, 1H, ArH), 7.97 (d, $J = 8.2$ Hz, 1H, ArH), 8.67 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.3, 27.5, 27.8, 39.8, 43.1, 56.9, 60.3, 71.5, 114.3, 118.2, 122.9, 125.6, 126.5, 128.9, 130.0, 141.7, 148.0, 149.7, 149.8; IR (film): 3072, 2940, 2866, 1719, 1590, 1507, 1452, 1098, 901, 804, 756, 635 cm⁻¹.

4.3.2. (1S,3R,4S,8S,9S)-6'-Methoxy-9-mercaptocinchonan (9-mercapto-epi-quinine, 9-HS-epi-QN) 3b

Yield 80%, white solid, mp 145–150 °C; $[\alpha]_D = -72.8$ (c 0.92, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.41–1.59 (m, 2H), 1.68–1.81 (m, 3H), 2.23–2.28 (m, 1H), 2.61–2.69 (m, 2H), 3.04–3.16 (m, 2H), 3.40–3.46 (m, 1H), 3.89 (s, 3H, OMe), 4.03 (br s, 1H, SH), 4.89–4.99 (m, 2H, CH₂=), 5.51 (d, $J = 4.3$ Hz, 1H, C⁹H), 5.68–5.80 (m, 1H, CH=), 7.22 (d, $J = 2.7$ Hz, 1H, ArH), 7.31 (dd, $J = 9.2$, 2.7 Hz, 1H, ArH), 7.48 (d, $J = 4.5$ Hz, 1H, ArH), 7.96 (d, $J = 9.2$ Hz, 1H, ArH), 8.60 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 21.7, 27.6, 27.9, 39.9, 43.2, 55.7, 57.0, 59.9, 71.9, 101.3, 114.4, 118.5, 121.5, 126.6, 131.4, 141.8, 144.1, 147.5, 147.8, 157.7; IR (film): 3073, 2933, 2859, 1622, 1508, 1470, 1241, 1032, 823, 717, 645 cm⁻¹.

4.3.3. (1S,3R,4S,8S,9S)-10,11-Dihydro-6'-methoxy-9-mercaptocinchonan (9-mercapto-epi-dihydroquinine, 9-HS-epi-DHQN) 3c

Yield 84%, solidified brown oil; $[\alpha]_D = -46.0$ (c 0.42, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.79 (t, $J = 7.3$ Hz, 3H, Me), 1.17–1.27 (m, 2H), 1.40–1.43 (m, 3H), 1.71–1.78 (m, 3H), 2.34–2.44 (m, 1H), 2.60–2.68 (m, 1H), 3.01–3.09 (m, 2H), 3.46–3.51 (m, 1H), 3.86 (s, 3H, OMe), 4.71 (br s, 1H, SH), 5.57 (d, $J = 3.3$ Hz, 1H, C⁹H), 7.22–7.30 (m, 2H, ArH), 7.50 (d, $J = 4.5$ Hz, 1H, ArH), 7.93 (d, $J = 9.2$ Hz, 1H, ArH), 8.59 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 11.9, 20.9, 25.3, 27.5, 27.8, 37.2, 43.3, 55.8, 58.3, 59.7, 71.1, 101.2, 118.5, 121.4, 126.5, 131.3, 144.0, 147.4, 147.9, 157.6; IR (film): 2931, 2870, 1621, 1508, 1461, 1241, 1030, 829, 717, 642 cm⁻¹.

4.3.4. (1S,3R,4S,8R,9R)-6'-Methoxy-9-mercaptocinchonan (9-mercapto-epi-quinidine, 9-HS-epi-QD) 3d

Yield 93%, solidified yellow oil; $[\alpha]_D = +148.9$ (c 0.90, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.11–1.15 (m, 1H), 1.47–1.59 (m, 2H), 1.74–1.78 (m, 1H), 2.03–2.11 (m, 1H), 2.23–2.28 (m, 1H), 2.74–3.08 (m, 4H), 3.39–3.46 (m, 1H), 3.77 (s, 3H, OMe), 5.00–5.12 (m, 3H, CH₂=, SH), 5.66 (d, $J = 3.6$ Hz, 1H, C⁹H), 5.98–6.10 (m, 1H, CH=), 7.15 (d, $J = 2.6$ Hz, 1H, ArH), 7.25–7.29 (m, 1H, ArH), 7.53 (d, $J = 4.5$ Hz, 1H, ArH), 7.93 (d, $J = 9.2$ Hz, 1H, ArH), 8.60 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 20.8, 26.2, 28.2, 39.9, 49.5, 50.1, 55.6, 59.7, 71.5, 101.1, 114.8, 118.5, 121.5, 126.5, 131.5, 140.4, 144.1, 147.5, 147.7, 157.7; IR (film): 3070, 2938, 2871, 1621, 1509, 1262, 1041, 832, 757, 664 cm⁻¹.

4.3.5. (1S,3R,4S,8R,9R)-10,11-Dihydro-6'-methoxy-9-mercaptocinchonan (9-mercapto-epi-dihydroquinidine, 9-HS-epi-DHQD) 3e

Yield 77%, solidified brown oil; $[\alpha]_D = +141.4$ (c 0.29, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.78 (t, $J = 7.1$ Hz, 3H, Me), 0.98–1.07 (m, 1H), 1.35–1.49 (m, 5H), 1.60–1.64 (m, 1H), 1.87–1.95 (m, 1H), 2.66–2.74 (m, 1H), 2.78–2.85 (m, 2H), 2.96–3.08 (m, 2H), 3.72 (s, 3H, OMe), 5.63 (s, 1H, C⁹H), 7.08 (d, $J = 2.5$ Hz, 1H, ArH), 7.21 (d, $J = 2.5$ Hz, 1H, ArH), 7.46 (d, $J = 4.5$ Hz, 1H, ArH), 7.86 (d, $J = 9.2$ Hz, 1H, ArH), 8.58 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 11.9, 20.6, 25.0, 26.1, 26.1, 37.0, 50.1, 51.0, 55.7, 59.8, 71.1, 101.0, 118.5, 121.5, 126.4, 131.5, 144.1, 147.2, 147.5, 157.7; IR (film): 2933, 2870, 1622, 1509, 1471, 1241, 1030, 830, 718, 641 cm⁻¹.

4.3.6. (1S,3R,4S,8S,9R)-6'-Methoxy-9-mercaptocinchonan (9-mercapto-quinine, 9-HS-QN) 3f

Yield 93%, solidified yellow oil; $[\alpha]_D = +23.7$ (c 0.38, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.88–0.95 (m, 1H), 1.37–1.46 (m, 1H), 1.54–1.67 (m, 3H), 2.21–2.30 (m, 1H), 2.70–2.79 (m, 2H), 3.03–3.26 (m, 3H), 3.89 (s, 3H, OMe), 4.88–5.06 (m, 4H, CH₂=, C⁹H, SH), 5.63–5.75 (m, 1H, CH=), 7.30–7.36 (m, 2H, ArH), 7.59 (d, $J = 2.6$ Hz, 1H, ArH), 7.97 (d, $J = 9.2$ Hz, 1H, ArH); 8.69 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 23.4, 25.2, 28.1, 40.0, 40.8, 55.5, 56.0, 61.6, 71.4, 102.7, 114.7, 120.2, 121.3, 128.2, 131.7, 141.5, 144.4, 144.9, 147.6, 157.5; IR (film): 2927, 2861, 1622, 1508, 1474, 1241, 1031, 832, 716, 640 cm⁻¹.

4.3.7. (1S,3R,4S,8R,9S)-6'-Methoxy-9-mercaptocinchonan (9-mercapto-quinidine, 9-HS-QD) 3g

Yield 65%, solidified yellow oil; $[\alpha]_D = +106.0$ (c 0.50, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.00–1.06 (m, 1H), 1.31–1.39 (m, 1H), 1.54–1.60 (m, 2H), 1.71–1.73 (m, 1H), 2.33–2.36 (m, 2H), 2.92–3.02 (m, 4H), 3.94 (s, 3H, OMe), 5.05–5.16 (m, 4H, CH₂=, C⁹H, SH), 5.86–5.96 (m, 1H, CH=), 7.37 (dd, $J = 9.2$, 2.7 Hz, 1H, ArH); 7.48 (d, $J = 4.5$ Hz, 1H, ArH), 7.58 (d, $J = 2.7$ Hz, 1H, ArH), 8.02 (d, $J = 9.2$ Hz, 1H, ArH); 8.75 (d, $J = 4.5$ Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 24.0, 26.6, 27.3, 39.0, 46.8, 49.2, 55.4, 62.2, 70.1, 101.9, 114.7, 119.9, 121.6, 128.0, 131.6, 140.2, 144.7, 144.9, 147.6, 157.4; IR (film): 2935, 2870, 1621, 1507, 1474, 1241, 1030, 827, 715, 639 cm⁻¹.

4.4. Representative procedure for the preparation of disulfides of alkaloids 4

An aqueous solution of 20% NaOH (0.060 g, 1.5 mmol) was added to a stirred solution of the appropriate thiols of alkaloids (1 mmol) dissolved in EtOH (10 mL). Then a solution of I₂ (0.095 g, 0.75 mmol) in EtOH (ca. 5 mL) was added dropwise until the color of the mixture become permanent. The reaction mixture was stirred at rt overnight. Thereafter EtOH was evaporated and the residue was quenched by the addition of satd Na₂S₂O₃ (10 mL) and extracted with CH₂Cl₂ (3 × 10 mL) and the combined organic phase was washed with water, brine, dried (Na₂SO₄) and evaporated under reduced pressure to afford a yellow solid.

4.4.1. Bis((1S,3R,4S,8S,9S)-cinchonan-9-yl)disulfide (bis(9-*epi*-cinchonidinyl)disulfide, 9-*epi*-CD-S-)₂ 4a

Yield 90%, yellow solid, mp >220 °C with decomposition; [α]_D = -35.0 (c 0.52, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.34–1.46 (m, 2H), 1.72–1.76 (m, 3H), 2.22–2.26 (m, 1H), 2.58–2.66 (m, 2H), 3.00–3.08 (m, 2H), 3.54–3.58 (m, 1H), 4.80–4.89 (m, 2H, CH₂=), 5.52–5.64 (m, 1H, CH=), 5.77 (s, 1H, C⁹H), 7.26 (t, J = 7.4 Hz, 1H, ArH), 7.50–7.55 (m, 2H, ArH), 7.89–7.98 (m, 2H, ArH), 8.71 (d, J = 4.4 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 20.3, 26.3, 27.5, 38.8, 43.6, 56.1, 60.4, 69.6, 115.5, 118.4, 122.9, 125.1, 126.5, 129.1, 130.0, 139.9, 147.9, 148.0, 150.0; IR (film): 3072, 2939, 2866, 2726, 1590, 1508, 1452, 1097, 901, 804, 756, 635, 576 cm⁻¹. Anal. Calcd for C₃₈H₄₂N₄S₂ (M = 618.90): C, 73.75; H, 6.84; N, 9.05; S, 10.36. Found: C, 73.45; H, 6.54; N, 9.27; S, 10.18.

4.4.2. Bis((1S,3R,4S,8S,9S)-6'-methoxycinchonan-9-yl)disulfide (bis(9-*epi*-quininyl)disulfide, 9-*epi*-QN-S-)₂ 4b

Yield 99%, yellow solid, mp >220 °C with decomposition; [α]_D = -25.8 (c 0.66, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.44–1.58 (m, 2H), 1.81–1.88 (m, 3H), 2.36–2.39 (m, 1H), 2.63–2.79 (m, 2H), 3.07–3.23 (m, 2H), 3.63–3.75 (m, 1H), 3.88 (s, 3H, OMe), 4.92–5.00 (m, 2H, CH₂=), 5.63–5.74 (m, 1H, CH=), 5.80 (s, 1H, C⁹H), 7.19 (d, J = 2.6 Hz, 1H, ArH), 7.26–7.30 (m, 1H, ArH), 7.52 (d, J = 4.5 Hz, 1H, ArH), 7.92 (d, J = 9.2 Hz, 1H, ArH), 8.62 (d, J = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 19.5, 25.4, 26.4, 37.9, 42.8, 55.4, 55.6, 59.0, 68.8, 99.8, 114.5, 117.6, 120.9, 125.2, 130.3, 139.0, 142.9, 145.4, 146.3, 157.0; IR (film): 2927, 2866, 1620, 1590, 1508, 1453, 1241, 1097, 1028, 825, 717, 641, 569 cm⁻¹. Anal. Calcd for C₄₀H₄₆N₄O₂S₂ (M = 678.95): C, 70.76; H, 6.83; N, 8.25; S, 9.45. Found: C, 70.49; H, 6.71; N, 8.36; S, 9.21.

4.4.3. Bis((1S,3R,4S,8S,9S)-10,11-Dihydro-6'-methoxycinchonan-9-yl)disulfide (bis(9-*epi*-dihydroquininyl)disulfide, 9-*epi*-DHQN-S-)₂ 4c

Yield 98%, light brown solid, mp 220 °C with decomposition; [α]_D = -9.1 (c 0.32, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.73 (t, J = 7.2 Hz, 3H, Me), 1.10–1.24 (m, 2H), 1.70–1.81 (m, 3H), 1.96–2.17 (m, 3H), 2.59–2.64 (m, 1H), 3.00–3.06 (m, 1H), 3.23 (t, J = 9.1 Hz, 1H), 3.36 (t, J = 10.9 Hz, 1H), 3.62 (s, 3H, OMe), 4.47–4.91 (m, 1H), 6.38 (s, 1H, C⁹H), 6.86 (d, J = 2.3 Hz, 1H, ArH), 6.93 (dd, J = 9.3, 2.4 Hz, 1H, ArH), 7.61–7.66 (m, 2H, ArH), 8.61 (d, J = 4.5 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 10.4, 17.0, 23.5, 23.6, 25.9, 34.4, 43.3, 56.0, 56.7, 59.0, 65.0, 99.1, 118.1, 122.1, 124.6, 129.0, 140.9, 144.7, 144.9, 157.6; IR (film): 2930, 2875, 1620, 1591, 1508, 1459, 1241, 1025, 856, 718, 643, 566 cm⁻¹. Anal. Calcd for C₄₀H₅₀N₄O₂S₂ (M = 682.98): C, 70.34; H, 7.38; N, 8.20; S, 9.39. Found: C, 70.56; H, 7.62; N, 7.98; S, 9.11.

4.4.4. Bis((1S,3R,4S,8R,9R)-6'-methoxycinchonan-9-yl)disulfide (bis(9-*epi*-quinidinyl)disulfide, 9-*epi*-QD-S-)₂ 4d

Yield 96%, yellow solid, mp >220 °C with decomposition; [α]_D = +94.1 (c 0.34, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.05–1.14 (m, 1H), 1.50–1.75 (m, 2H), 1.81–1.85 (m, 1H), 2.18 (t,

J = 11.2 Hz, 1H), 2.32–2.35 (m, 1H), 2.82–3.16 (m, 5H), 3.77 (s, 3H, OMe), 5.08–5.13 (m, 2H, CH₂=), 5.97–6.10 (m, 2H, CH=, C⁹H), 7.14 (d, J = 2.1 Hz, 1H, ArH), 7.23 (dd, J = 9.2, 2.0 Hz, 1H, ArH), 7.58 (d, J = 4.4 Hz, 1H, ArH), 7.90 (d, J = 9.2 Hz, 1H, ArH), 8.65 (d, J = 4.4 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 24.4, 27.6, 29.5, 38.2, 40.1, 48.4, 49.2, 55.6, 56.3, 60.0, 101.7, 116.3, 118.9, 121.6, 126.3, 131.6, 138.4, 144.2, 147.4, 157.9; IR (film): 2934, 2871, 1621, 1591, 1508, 1455, 1241, 1028, 831, 718, 640, 570 cm⁻¹. Anal. Calcd for C₄₀H₄₆N₄O₂S₂ (M = 678.95): C, 70.76; H, 6.83; N, 8.25; S, 9.45. Found: C, 70.51; H, 6.98; N, 7.92; S, 9.07.

4.4.5. Bis((1S,3R,4S,8R,9R)-10,11-Dihydro-6'-methoxycinchonan-9-yl)disulfide (bis(9-*epi*-dihydroquinidinyl)disulfide, 9-*epi*-DHQD-S-)₂ 4e

Yield 88%, light brown solid, mp >230 °C with decomposition; [α]_D = +46.8 (c 0.24, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.94 (t, J = 7.3 Hz, 3H, Me), 1.56–1.81 (m, 5H), 1.94–2.02 (m, 2H), 2.38 (t, J = 11.4 Hz, 1H), 3.02–3.13 (m, 1H), 3.24–3.39 (m, 2H), 3.63 (s, 3H, OMe), 3.89–3.98 (m, 1H), 4.15–4.22 (m, 1H), 6.59 (s, 1H, C⁹H), 6.92 (d, J = 2.1 Hz, 1H, ArH), 7.01 (dd, J = 9.2, 2.1 Hz, 1H, ArH), 7.68–7.75 (m, 2H, ArH), 8.68 (d, J = 4.4 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 11.6, 17.6, 23.8, 24.3, 25.1, 35.2, 49.4, 50.1, 57.2, 60.1, 66.3, 99.7, 118.6, 122.3, 125.2, 131.2, 143.6, 144.1, 146.9, 158.1; IR (film): 2930, 2875, 1620, 1591, 1508, 1460, 1241, 1026, 832, 718, 641, 568 cm⁻¹. Anal. Calcd for C₄₀H₅₀N₄O₂S₂ (M = 682.98): C, 70.34; H, 7.38; N, 8.20; S, 9.39. Found: C, 69.98; H, 7.07; N, 7.96; S, 9.46.

4.4.6. Bis((1S,3R,4S,8S,9R)-6'-methoxycinchonan-9-yl)disulfide (bis(9-*quininyl*)disulfide, 9-QN-S-)₂ 4f

Yield 98%, brown solid, mp 138–144 °C with decomposition; [α]_D = +15.4 (c 0.26, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 1.04–1.11 (m, 1H), 1.52–1.63 (m, 1H), 1.68–1.85 (m, 3H), 2.45–2.51 (m, 1H), 2.97–3.07 (m, 2H), 3.43–3.66 (m, 3H), 3.95 (s, 3H, OMe), 5.03–5.12 (m, 2H, CH₂=), 5.26 (d, J = 10.0 Hz, 1H, C⁹H), 5.67–5.73 (m, 1H, CH=), 7.34–7.43 (m, 2H, ArH); 7.67 (d, J = 2.6 Hz, 1H, ArH), 8.02 (d, J = 9.2 Hz, 1H, ArH), 8.73 (d, J = 4.4 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 23.4, 25.4, 26.4, 29.7, 37.6, 54.5, 55.6, 56.4, 61.9, 102.3, 116.8, 120.4, 122.0, 125.1, 131.7, 138.1, 142.6, 144.8, 147.5, 158.1; IR (film): 2924, 1621, 1590, 1505, 1455, 1230, 1024, 920, 831, 715, 619 cm⁻¹. Anal. Calcd for C₄₀H₄₆N₄O₂S₂ (M = 678.95): C, 70.76; H, 6.83; N, 8.25; S, 9.45. Found: C, 69.81; H, 6.31; N, 7.88; S, 9.12.

4.4.7. Bis((1S,3R,4S,8R,9S)-6'-methoxycinchonan-9-yl)disulfide (bis(9-*quinidinyl*)disulfide, 9-QD-S-)₂ 4g

Yield 82%, brown solid, mp 135–142 °C; [α]_D = +73.0 (c 0.28, CH₂Cl₂). ¹H NMR (300 MHz, CDCl₃) δ 0.98–1.30 (m, 3H), 1.53–1.67 (m, 3H), 2.30–2.32 (m, 1H), 3.01–3.03 (m, 4H), 3.85 (s, 3H, OMe), 5.04–5.13 (m, 3H, CH₂=, C⁹H), 5.74–5.80 (m, 1H, CH=), 7.24–7.29 (m, 1H, ArH); 7.39 (d, J = 4.0 Hz, 1H, ArH), 7.47 (d, J = 2.2 Hz, 1H, ArH), 7.92 (d, J = 9.2 Hz, 1H, ArH); 8.65 (d, J = 4.4 Hz, 1H, ArH); ¹³C NMR (75 MHz, CDCl₃) δ 23.7, 25.8, 27.2, 38.3, 46.7, 49.1, 55.5, 62.5, 69.3, 101.8, 115.5, 120.0, 121.8, 127.8, 131.6, 139.2, 144.3, 144.7, 147.6, 157.7; IR (film): 2934, 2873, 1620, 1590, 1507, 1455, 1227, 1026, 829, 715, 639, 617 cm⁻¹. Anal. Calcd for C₄₀H₄₆N₄O₂S₂ (M = 678.95): C, 70.76; H, 6.83; N, 8.25; S, 9.45. Found: C, 71.02; H, 6.58; N, 7.96; S, 9.80.

4.5. General procedure for the copper-catalyzed Henry reaction

The ligand (0.06 mmol, 12 mol %) and Cu(OAc)₂·H₂O (10.0 mg, 0.05 mmol, 10 mol %) were dissolved in *i*-PrOH (1 mL) and the mixture was stirred for 3 h at rt to give either a blue or dark green solution. Then the respective aldehyde (0.5 mmol, 1 equiv) and nitroalkane (5.0 mmol, 10 equiv) were added with an additional 1 mL of *i*-PrOH. The reaction mixture was cooled to 0 °C (or

–20 °C). After 3 days, the crude product was isolated by column chromatography (hexane/AcOEt 6:1) to give β -nitroalcohol.

4.5.1. 2-Nitro-1-phenylethanol 5

Chromatographic purification (hexane/AcOEt 6:1), $R_f = 0.16$. Enantiomeric excess was determined by HPLC (Chiracel OD-H), hexane/*i*-PrOH 90:10, 1 mL/min, 225 nm, enantiomer I $t_R = 13.9$ min, enantiomer (S) $t_R = 17.3$ min. The absolute configuration was assigned by comparison of the retention times in HPLC and specific rotation signs with literature data.^{7d,h} $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 2.88 (d, $J = 3.3$ Hz, 1H), 4.51 (dd, $J = 13.3, 3.2$ Hz, 1H), 4.62 (dd, $J = 13.3, 9.4$ Hz, 1H), 5.48 (dd, $J = 9.4, 3.2$ Hz, 1H).

4.5.2. 1-Cyclohexyl-2-nitro-ethanol 6

Chromatographic purification (hexane/AcOEt 6:1), $R_f = 0.29$, gave a colorless oil (55 mg, 64%). Enantiomeric excess (75%) was determined by HPLC (Chiralpak AD-H), hexane/*i*-PrOH 97:3, 0.5 mL/min, 210 nm, major enantiomer (S) $t_R = 47.6$ min, minor enantiomer (R) $t_R = 44.3$ min; $[\alpha]_D = 13.6$ (c 0.48, CH_2Cl_2 , 75% ee). The absolute configuration was assigned by comparison of the retention times in HPLC and specific rotation signs with literature data.^{7d,h} $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.01–1.25 (m, 5H), 1.37–1.48 (m, 1H), 1.59–1.65 (m, 2H), 1.71–1.79 (m, 3H), 2.38 (d, $J = 4.4$ Hz, 1H), 4.01–4.07 (m, 1H), 4.36 (dd, $J = 13.1, 8.6$ Hz, 1H), 4.43 (dd, $J = 13.1, 3.2$ Hz, 1H).

4.5.3. 2-Nitro-1-phenylpropanol 7

Chromatographic purification (hexane/AcOEt 6:1), $R_f = 0.20$. Diastereomeric ratios were determined by $^1\text{H NMR}$. Enantiomeric excesses were determined by HPLC (Chiralpak AD-H), hexane/*i*-PrOH 95:5, 1 mL/min, 225 nm, *anti*_{major} (1S,2R) $t_R = 13.5$, *anti*_{minor} (1R,2S) $t_R = 15.3$, *syn*_{major} (1S,2S) $t_R = 18.7$, *syn*_{minor} (1R,2R) $t_R = 21.0$. The absolute configuration of both diastereomers was assigned by comparison of the retention times in HPLC with literature data;^{7d,f,j,9c} *syn isomer* (1S,2S): $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.48 (d, $J = 6.8$ Hz, 3H), 2.69 (d, $J = 3.4$ Hz, 1H), 4.67 (dq, $J = 6.8, 3.6$ Hz, 1H), 5.38 (t, $J = 3.3$ Hz, 1H), 7.30–7.40 (m, 5H, ArH); *anti isomer* (1S,2R): $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.48 (d, $J = 6.8$ Hz, 3H), 2.69 (d, $J = 3.4$ Hz, 1H), 4.67 (dq, $J = 6.8, 3.6$ Hz, 1H), 5.38 (t, $J = 3.3$ Hz, 1H), 7.30–7.40 (m, 5H, ArH).

4.5.4. 2-Nitro-1,3-diphenylpropanol 8

Chromatographic purification (hexane/AcOEt 6:1), $R_f = 0.19$, gave a white solid (91 mg, 71%). Diastereomeric ratios (*anti*/*syn*, 57:43) were determined by $^1\text{H NMR}$. Enantiomeric excesses were determined by HPLC (Chiracel OD-H), hexane/*i*-PrOH 90:10, 1 mL/min, 210 nm, *anti*_{major} (1S,2R) $t_R = 14.2$, *anti*_{minor} (1R,2S) $t_R = 10.6$, *syn*_{major} (1S,2S) $t_R = 18.7$, *syn*_{minor} (1R,2R) $t_R = 12.6$. The absolute configuration of both diastereomers was assigned by comparison of the retention times in HPLC with literature data;^{7d} *anti isomer* (1S,2R), 61% ee: $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 2.65 (s, 1H), 3.07 (dd, $J = 14.6, 2.9$ Hz, 1H), 3.35 (dd, $J = 14.9, 10.9$ Hz, 1H), 4.82–4.89 (m, 1H), 5.23 (d, $J = 4.6$ Hz, 1H), 6.97–7.02 (m, 2H, ArH), 7.14–7.23 (m, 3H, ArH), 7.28–7.38 (m, 5H, ArH); *syn isomer* (1S,2S), 74% ee: $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 2.53 (s, 1H), 2.71 (dd, $J = 14.4, 3.8$ Hz, 1H), 3.08

(dd, $J = 11.1, 7.4$ Hz, 1H), 4.82–4.89 (m, 1H), 5.04 (d, $J = 6.5$ Hz, 1H), 6.97–7.02 (m, 2H, ArH), 7.14–7.23 (m, 3H, ArH), 7.28–7.38 (m, 5H, ArH).

Acknowledgment

We are grateful to the Ministry of Science and Higher Education for financial support (Grant No. N204 161036).

References

- (a) *Catalysis in Asymmetric Synthesis*; Ojima, I., Ed., 2nd ed.; Wiley-VCH: New York, 2000; (b) Yoon, T. P.; Jacobsen, E. N. *Science* **2003**, *299*, 1691–1693.
- (a) Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa, K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. *J. Org. Chem.* **1992**, *57*, 2768–2771; (b) Becker, H.; Sharpless, K. B. *Angew. Chem., Int. Ed.* **1996**, *35*, 448–451; (c) Kacprzak, K.; Gawroński, J. *Synthesis* **2001**, 961–998; (d) McDavid, P.; Chen, Y.; Deng, L. *Angew. Chem., Int. Ed.* **2002**, *41*, 338–340; (e) Kim, H. S.; Song, Y.-M.; Choi, J. S.; Yang, J. W.; Han, H. *Tetrahedron* **2004**, *60*, 12051–12057; (f) Poulsen, T. B.; Alemparte, C.; Jørgensen, K. A. *J. Am. Chem. Soc.* **2005**, *127*, 11614–11615; (g) Ishimaru, T.; Shibata, N.; Horikawa, T.; Yasuda, N.; Nakamura, S.; Toru, T.; Shiro, M. *Angew. Chem., Int. Ed.* **2008**, *47*, 4157–4161.
- (a) Zielińska-Błajet, M.; Kucharska, M.; Skarzewski, J. *Synthesis* **2006**, 1176–1182; (b) Zielińska-Błajet, M.; Siedlecka, R.; Skarzewski, J. *Tetrahedron: Asymmetry* **2007**, *18*, 131–136.
- (a) Pellissier, H. *Tetrahedron* **2007**, *63*, 1297–1330; (b) Mellah, M.; Voituriez, A.; Schulz, E. *Chem. Rev.* **2007**, *107*, 5133–5209; (c) Paulsen, T. B.; Jørgensen, K. A. *Chem. Rev.* **2008**, *108*, 2903–2915.
- For recent examples of S/N complexes with copper, see: (a) Mandal, S.; Das, G.; Singh, R.; Shukla, R.; Bharadwaj, P. K. *Coord. Chem. Rev.* **1997**, *160*, 191–235; (b) Chou, J.-L.; Chyn, J.-P.; Urbach, F. L.; Gervasio, D. F. *Polyhedron* **2000**, *19*, 2215–2223; (c) Ohta, T.; Tachiyama, T.; Yoshizawa, K.; Yamabe, T. *Tetrahedron Lett.* **2000**, *41*, 2581–2585; (d) Ohta, T.; Tachiyama, T.; Yoshizawa, K.; Yamabe, T.; Uchida, T.; Kitagawa, T. *Inorg. Chem.* **2000**, *39*, 4358–4369; (e) West, D. X.; Swearingen, J. K.; Romack, T. J.; Billeh, I. S.; Jasinski, J. P.; Li, Y.; Staples, R. J. *J. Mol. Struct.* **2001**, *570*, 129–136; (f) Gao, J.; Martell, A. E. *Org. Biomol. Chem.* **2003**, *1*, 2801–2806; (g) Mukherjee, R. In *Comprehensive Coordination Chemistry II*; Elsevier: Pergamon, Oxford, 2004; Vol. 6, pp 826–827, 895–896; (h) Lee, Y.; Lee, D.-H.; Sarjeant, A. N.; Karlin, K. D. *J. Inorg. Chem.* **2007**, *101*, 1845–1858.
- Cinchona* alkaloids were used as organocatalysts: (a) Marcelli, T.; van der Haas, R. N. S.; van der Maarseveen, J. H.; Hiemstra, H. *Synlett* **2005**, 2817–2819; (b) Vakulya, B.; Varga, S.; Csampai, A.; Soos, T. *Org. Lett.* **2005**, *7*, 1967–1969; (c) McCooney, S. H.; Connon, S. J. *Angew. Chem., Int. Ed.* **2005**, *44*, 6367–6370; (d) Ye, J.; Dixon, D. J.; Hines, P. S. *Chem. Commun.* **2005**, 4481–4483; (e) Marcelli, T.; van der Haas, R. N. S.; van der Maarseveen, J. H.; Hiemstra, H. *Angew. Chem., Int. Ed.* **2006**, *45*, 929–931; (f) Li, H.; Wang, B.; Deng, L. *J. Am. Chem. Soc.* **2006**, *128*, 732–733.
- For recent reviews, see: (a) Boruwa, J.; Gogoi, N.; Saikia, P. P.; Barua, N. C. *Tetrahedron: Asymmetry* **2006**, *17*, 3315–3326; (b) Palomo, C.; Oiarbide, M.; Laso, A. *Eur. J. Org. Chem.* **2007**, 2561–2574; For the latest examples of the asymmetric nitroaldol reaction, see: (c) Arai, T.; Yokoyama, N.; Yanagisawa, A. *Chem. Eur. J.* **2008**, *14*, 2052–2059; (d) Blay, G.; Domingo, L. R.; Hernandez-Olmos, V.; Pedro, J. R. *Chem. Eur. J.* **2008**, *14*, 4725–4730; (e) Arai, T.; Yokoyama, N. *Angew. Chem., Int. Ed.* **2008**, *47*, 4989–4992; (f) Liu, S.; Wolf, C. *Org. Lett.* **2008**, *10*, 1831–1834; (g) Bulut, A.; Aslan, A.; Dogan, O. *J. Org. Chem.* **2008**, *73*, 7373–7375; (h) Kowalczyk, R.; Sidorowicz, Ł.; Skarzewski, J. *Tetrahedron: Asymmetry* **2008**, *10*, 2310–2315; (i) Bandidni, M.; Sinisi, R.; Umani-Ronchi, A. *Chem. Commun.* **2008**, 4360–4362; (j) Toussaint, A.; Pfaltz, A. *Eur. J. Org. Chem.* **2008**, 4591–4597; (k) Kowalczyk, R.; wiatkowski, P.; Skarzewski, J.; Jurczak, J. *J. Org. Chem.* **2009**, *74*, 753–756.
- Volante, R. P. *Tetrahedron Lett.* **1981**, *22*, 3119–3122.
- (a) Christensen, C.; Juhl, K.; Hazell, R. G.; Jørgensen, K. A. *J. Org. Chem.* **2002**, *67*, 4875–4881; (b) Evans, D. A.; Seidel, D.; Rueping, M.; Lam, W. H.; Shaw, J. T.; Downey, C. W. *J. Am. Chem. Soc.* **2003**, *125*, 12692–12693; (c) Purkarthofer, T.; Gruber, K.; Gruber-Khadjawi, M.; Waich, K.; Skranc, W.; Mink, D.; Griengl, H. *Angew. Chem., Int. Ed.* **2006**, *45*, 3454–3456.